Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19

Sai Kiran S.S. Pindiprolu, Sai Harshini Pindiprolu

School of Pharmaceutical Sciences and Technologies, JNTUK, Kakinada, India
Sree Sai Dental College and Research Institute, Srikakulam 532001, Andhra Pradesh, India

ARTICLE INFO

Keywords:
COVID-19
SARS-CoV-2
Drug discovery
Repurposing
Niclosamide

ABSTRACT

Corona virus disease 2019 (COVID-19) pandemic caused 18 440 deaths world wide as of 25 March 2020 and posing a serious threat to public health. There is a need, therefore, for effective therapeutic strategies to cure this disease. However, high attrition rates, substantial costs and slow pace are the major limitations of novel drug discovery. Drug repurposing, by employing 'old' drugs to treat 'new' diseases is an attractive approach in drug discovery. Niclosamide (NIC) is an approved anti-helminthic drug with diverse antiviral mechanisms. In this work we hypothesize, the potential antiviral mechanisms of NIC against COVID-19.

Introduction

Coronaviruses (CoV) are divided into four genera, α and β CoV infect mammals, while γ and δ CoV tend to infect birds. There are six human-susceptible CoVs are reported till date. α-CoVs, HCoV-229E and HCoV-NL63, and β-CoVs, HCoV-HKU1 and HCoV-OC43 causes mild respiratory symptoms similar to a common cold. The other two known β-CoVs, SARS-CoV and MERS-CoV are responsible for severe and potentially fatal respiratory tract infections [1–3].

Corona virus infectious disease 2019 (COVID-19), caused by novel corona virus, SARS-CoV-2 is an emerging infectious disease posing a serious threat to public health [4]. SARS-CoV-2 is a β-corona virus, first identified in Wuhan, China. Recently world health organisation (WHO) declared COVID-19 as a pandemic. As of 25 March 2020, there were nearly 18 440 deaths occurred worldwide due to COVID-19. However, there are no clinically approved vaccines or therapeutic agents are available for treating COVID-19 [5,6]. Researchers, therefore, focused on discovery of novel anti-viral agents against this pandemic. However, high attrition rates, substantial costs and slow pace are the major limitations for discovery of new drugs against this emerging pandemic [7].

Drug repurposing/repositioning is a strategy of identifying newer therapeutic applications for existing clinically approved drugs [8]. This can be an effective approach to accelerate drug discovery process against emerging pandemics like COVID-19. Niclosamide (NIC) is an FDA approved anthelmintic drug. Recent drug repurpose screening identified NIC as an antimetabolite, antibacterial and anticancer agent [9,10]. Compelling body of evidences also suggest NIC also possess broad spectrum antiviral properties including SARS-CoV (IC50 = 1.56 µM) [11,12]. Recently, it was also reported that, NIC exhibited in vitro antiviral activity against SARS-CoV-2 (IC50 = 0.28 µM) [13]. NIC, therefore, can therefore be a potential drug candidate for COVID-19. The plausible therapeutic mechanisms by which NIC acts as an antiviral agent against COVID-19 were presented in this work.

Plausible antiviral mechanisms of NIC against COVID-19

Spike (S) protein, 3C-like main protease, NTPase/helicase, RNA-dependent RNA polymerase (RNA replicate) and host receptors are the crucial drug targets of SARS-CoV-2 [1,14]. The following pharmacological mechanisms may contribute to the antiviral propensity of NIC against COVID-19.

i. NIC can block endocytosis of SARS-CoV-2

SARS-CoV-2 infects the permissive cells through the receptor of angiotensins converting enzyme-2 (ACE-2). Following receptor binding and induced conformational changes of S-protein, cathepsin L proteolysis occurs within endosomes for viral entry into host cells [15,16].
NIC was reported to pH dependent endocytosis of human rhinovirus (HRV) and influenza [17]. This mechanism may also contribute to the antiviral effects of NIC against SAR-CoV-2. The ACE-2 inhibitory activity of NIC, however, need to be confirmed.

ii. NIC can prevent autophagy of SARS-CoV-2 by inhibition of S-Phase kinase associated protein 2 (SKP2)

Recently it was reported that, NIC inhibited SKP2 and enhanced autophagy and reduced the replication of MERS-CoV replication [18]. This can be the potential antiviral mechanism of NIC against SARS-CoV-2 (Fig. 1).

**Conclusion**

Drug repurposing is an attractive approach for bringing new drugs quickly into market. Various drug repurposing screens identified NIC as a potential drug candidate against COVID-19. Prevention of viral entry by altering endosomal pH and prevention of viral replication by inhibition of autophagy are the plausible mechanisms of NIC against COVID-19. Clinical efficacy of NIC against COVID-19, therefore, need to be evaluated against COVID-19.

**Competing interests**

None to declare.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.mehy.2020.109765.

**References**

[1] Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. Mil Med Res 2020;7:1–10.
[2] McIntosh K. Current topics in microbiology and immunology/Ergebnisse der Mikrobiologie und Immunitätsforschung. Springer; 1974. p. 85–129.
[3] Yin Y, Wunderink RG. Respiratory 2018;25:190–7.
[4] Novel CPERE. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 2020;41:145.
[5] W. H. Organization; 2020.
[6] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Lancet Respir Med 2020.
[7] Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Nat Rev Drug Discovery 2019;18:41–58.
[8] Greener M. Prescriber 2017;28:34–8.
[9] Pindiprolu SH, Pindiprolu SKS. Med Hypotheses 2019;129:109241.
[10] Pan J-X, Ding K, Wang C-Y. Chin J Cancer 2012;31:178.
[11] Xu J, Shi P-Y, Li H, Zhou J. ACS Infect Dis 2020.
[12] Wu C-J, Jan J-T, Chen C-M, Hsieh H-P, Hwang D-R, Liu H-W, et al. Antimicrob Agents Chemother 2004;48:2693–6.
[13] Ko M, Chang SY, Byun SY, Choi I, d’Alexandry ALPH, Shum D, Min J-Y, Windisch MP. bioRxiv 2020.
[14] De Clercq E. Expert Rev Anti-infective Therapy 2006;4:291–302.
[15] Beniac DR, Andonov A, Grudeski E, Booth TF. Nat Struct Mol Biol 2006;13:751–2.
[16] Thomson G. Int J Clin Pract 2020;e13503.
[17] Jurgeit A, McDowell R, Moese S, Meldrum E, Schwendener R, Greber UF. PloS Pathog 2012;8.
[18] Gassen NC, Niemeyer D, Muth D, Corman VM, Martinelli S, Gassen A, et al. Nat Commun 2019;10:1–16.